Please enter the email address you used to register, then we will send you a link to choose a new password
Within this landscape, GT Biopharma (NASDAQ:GTBP) is advancing a proprietary platform designed to harness NK cells against can...
GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.68) ...
The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful...